journal article·2024-10Open access

Photoporation of NK-92MI cells with biodegradable polydopamine nanosensitizers as a promising strategy for the generation of engineered NK cell therapies

Charlotte Hinnekens, Aranit Harizaj, Dominika Berdecka, Ilke Aernout, Molood Shariati, Stefanie Peeters, Eva Lion, Stefaan C. De Smedt, Bart Vandekerckhove, Kevin Braeckmans, Juan C. Fraire

Abstract

Abstract: Chimeric antigen receptor (CAR)-T cells have made significant advancements in the field of adoptive immune cell therapies and the treatment of hematological malignancies. However, there are several drawbacks associated with the production and administration of these therapies. As a result, there has been interest in using natural killer (NK) cells to develop allogeneic CAR-NK cell therapies instead. While viral transduction is powerful for engineering T cells, NK cells have shown limited efficacy and high toxicity with this method. Therefore, efforts are being made to optimize non-viral transfection technologies for engineering NK cells. One such emerging technology is photoporation, which has demonstrated high efficiency and versatility for transfecting different immune cells. In this study, we evaluated the potential of nanoparticle-sensitized photoporation for genetic engineering of NK cells. Our findings show that both FD500 and eGFP mRNA can be successfully delivered into NK-92MI cells with high efficiency and low toxicity. When compared to state-of-the-art electroporation, photoporation proved to be more efficient, gentle, and capable of preserving the phenotype of NK-92MI cells. Overall, our work highlights the promising prospects of photoporation for NK cell engineering.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Surface Modification and Superhydrophobicity · CAR-T cell therapy research · Immune Cell Function and Interaction

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (67)

Show source-provided references
1. CAR immune cells: design principles, resistance and the next generation10.1038/s41586-023-05707-3 ↗
2. From bench to bedside: the history and progress of CAR T cell therapy10.3389/fimmu.2023.1188049 ↗
3. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy10.1111/bjh.15644 ↗
4. Allogeneic natural killer cell therapy10.1182/blood.2022016200 ↗
5. From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies
6. CAR-NK cells: the next wave of cellular therapy for cancer10.1002/cti2.1274 ↗
7. Cells NK cells armed with chimeric antigen receptors (CAR): roadblocks to Successful Development
8. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies10.1186/s13045-022-01382-5 ↗
9. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies10.1186/s13287-021-02462-y ↗
10. Non-viral engineering of NK cells10.1016/j.biotechadv.2023.108212 ↗
11. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy10.1038/s41598-022-23589-9 ↗
12. Improving CAR T cell therapy by optimizing critical quality attributes10.1053/j.seminhematol.2020.07.005 ↗
13. Current approaches to develop ‘off-the-shelf’ chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review10.1186/s40164-023-00435-w ↗
14. Use of allogeneic NK cells for cancer immunotherapy10.2217/imt.11.131 ↗
15. Off-the-shelf CAR T cells for multiple myeloma10.1038/s41591-022-02195-2 ↗
16. Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods10.1016/j.jcyt.2019.01.003 ↗
17. Clinical manufacturing of CAR T cells: foundation of a promising therapy10.1038/mto.2016.15 ↗
18. Non-viral transfection technologies for next-generation therapeutic T cell engineering10.1016/j.biotechadv.2021.107760 ↗
19. CAR T-Cell Production Using Nonviral Approaches10.1155/2021/6644685 ↗
20. Non-viral chimeric antigen receptor (CAR) T cells going viral
21. Engineering NK cells for CAR therapy—recent advances in gene transfer methodology10.3389/fimmu.2020.611163 ↗
22. Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer10.1016/j.surg.2019.05.047 ↗
23. High-­ affinity­CD16­integration­into­a­ CRISPR/Cas9-­ edited­CD38­locus­ augments­CD38-­ directed­antitumor­ activity­of­primary­human­natural­ killer­cells
24. CRISPR-Targeted CAR Gene Insertion Using Cas9/RNP and AAV6 Enhances Anti-AML Activity of Primary NK Cells
25. A robust platform for expansion and genome editing of primary human natural killer cells10.1084/jem.20201529 ↗
26. Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo10.1073/pnas.1809671115 ↗
27. Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy10.1182/bloodadvances.2020002355 ↗
28. Delivery of macromolecules in unstimulated T cells by photoporation with polydopamine nanoparticles10.1016/j.jconrel.2023.01.047 ↗
29. Photoporation with Biodegradable Polydopamine Nanosensitizers Enables Safe and Efficient Delivery of mRNA in Human T Cells10.1002/adfm.202102472 ↗
30. Gold nanoparticle-mediated photoporation enables delivery of macromolecules over a wide range of molecular weights in human CD4+ T cells10.3390/cryst9080411 ↗
31. Targeted perturbation of nuclear envelope integrity with vapor nanobubble-mediated photoporation10.1021/acsnano.8b01860 ↗
32. Vapor nanobubble is the more reliable photothermal mechanism for inducing endosomal escape of siRNA without disturbing cell homeostasis10.1016/j.jconrel.2019.12.050 ↗
33. Lukianova-Hleb · 2010 · 2109
34. Laser-assisted photoporation: fundamentals, technological advances and applications
35. Cas9 RNP transfection by vapor nanobubble photoporation for ex vivo cell engineering10.1016/j.omtn.2021.08.014 ↗
36. Comparing photoporation and nucleofection for delivery of small interfering RNA to cytotoxic T cells10.1016/j.jconrel.2017.08.002 ↗
37. Size-Dependent Cytotoxicity of Gold Nanoparticles10.1002/smll.200700378 ↗
38. Gold nanoparticles: distribution, bioaccumulation and toxicity. In vitro and in vivo studies10.1016/j.nano.2017.08.011 ↗
39. s
40. Aneuploidogenic effects and DNA oxidation induced in vitro by differently sized gold nanoparticles10.2147/IJN.S58397 ↗
41. Response Surface Methodology to Efficiently Optimize Intracellular Delivery by Photoporation10.3390/ijms24043147 ↗
42. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins10.3389/fimmu.2020.01008 ↗
43. CD56bright cells respond to stimulation until very advanced age revealing increased expression of cellular protective proteins SIRT1, HSP70 and SOD2
44. Human natural killer cells exhibit negative regulatory function by ectopic expression of hfoxp3 gene10.1097/TP.0b013e318290b086 ↗
45. Cooper · 2001
46. Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy10.1016/j.stem.2018.07.007 ↗
47. Next-generation cell therapies: the emerging role of CAR-NK cells10.1182/hematology.2020002547 ↗
48. Williams · 2017 · 8 · 89256
49. NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy10.1007/s00262-015-1761-x ↗
50. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity10.3389/fimmu.2017.00533 ↗
51. Magnetic delivery of Fe 3 O 4@polydopamine nanoparticle-loaded natural killer cells suggest a promising anticancer treatment10.1039/C8BM00588E ↗
52. Attenuation of the in vivo toxicity of biomaterials by polydopamine surface modification10.2217/nnm.11.76 ↗
53. Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer10.1002/smll.201301992 ↗
54. Anticancer nano-delivery systems based on bovine serum albumin nanoparticles: a critical review10.1016/j.ijbiomac.2021.10.040 ↗
55. Recent progress in the biomedical applications of polydopamine nanostructures10.1039/C7BM00187H ↗
56. Albumin-stabilized polydopamine nanoparticles for chemo-photothermal synergistic therapy of melanoma
57. A Biocompatible and Biodegradable Protein Hydrogel with Green and Red Autofluorescence: preparation, Characterization and in Vivo Biodegradation Tracking and Modeling
58. Mussel-inspired polydopamine: a biocompatible and ultrastable coating for nanoparticles in vivo10.1021/nn404117j ↗
59. Bioinspired polymerization of dopamine to generate melanin-like nanoparticles having an excellent free-radical-scavenging property10.1021/bm101281b ↗
60. Polydopamine Nanomaterials for Overcoming Current Challenges in Cancer Treatment10.3390/nano13101656 ↗
61. From bioinspired glue to medicine: polydopamine as a biomedical material10.3390/ma13071730 ↗
62. Intracellular delivery by membrane disruption: mechanisms, strategies, and concepts10.1021/acs.chemrev.7b00678 ↗
63. Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo10.1016/j.omtm.2021.03.007 ↗
64. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection10.1038/nature21405 ↗
65. Photothermal nanofibres enable safe engineering of therapeutic cells
66. Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells10.1016/j.jconrel.2023.08.014 ↗
67. Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles10.1016/j.ijpharm.2023.122810 ↗